SRR1330346
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.431
- PANCREAS_BETA_CELLS+0.406
- ANGIOGENESIS+0.317
- COAGULATION+0.281
- ESTROGEN_RESPONSE_LATE+0.234
- INFLAMMATORY_RESPONSE+0.233
- BILE_ACID_METABOLISM+0.193
- TNFA_SIGNALING_VIA_NFKB+0.193
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.192
- XENOBIOTIC_METABOLISM+0.164
Top 10 suppressed
- MYC_TARGETS_V1-0.593
- PROTEIN_SECRETION-0.538
- DNA_REPAIR-0.527
- MYC_TARGETS_V2-0.514
- UNFOLDED_PROTEIN_RESPONSE-0.478
- OXIDATIVE_PHOSPHORYLATION-0.447
- PI3K_AKT_MTOR_SIGNALING-0.399
- MITOTIC_SPINDLE-0.393
- E2F_TARGETS-0.388
- MTORC1_SIGNALING-0.379
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1353221 | GTEX | — | 0.957 |
| 2 | SRR1392725 | GTEX | — | 0.955 |
| 3 | SRR1475022 | GTEX | — | 0.953 |
| 4 | SRR1432765 | GTEX | — | 0.951 |
| 5 | SRR1440962 | GTEX | — | 0.948 |
| 6 | SRR1382956 | GTEX | — | 0.947 |
| 7 | SRR1330061 | GTEX | — | 0.946 |
| 8 | SRR1418604 | GTEX | — | 0.946 |
| 9 | SRR1367128 | GTEX | — | 0.944 |
| 10 | SRR1444559 | GTEX | — | 0.943 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.431 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.406 | Cobimetinib | — uncovered |
| ANGIOGENESIS | 0.317 | Remibrutinib | — uncovered |
| COAGULATION | 0.281 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.234 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.233 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.193 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.193 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.192 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.164 | Inavolisib | — uncovered |
| MYOGENESIS | 0.154 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.150 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.125 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.120 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.116 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.053 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.023 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.006 | Idelalisib | — uncovered |